TABLE 1.
Crohn’s disease patients clinical/demographic table, non-surgical (NS) and surgical (S) groups.
| Patients | Age at enrollment | Gender | Disease classification (Montreal) and simple endoscopic score SES-CD at enrollment | Biopsy’s location | Treatment at enrollment | |
|---|---|---|---|---|---|---|
| Diseased | Healthy | |||||
| NS-01 | 22 | male | SES-CD 10 | ileum | ileum | Imuran 75 mg daily; entocort EC 9 mg daily; stelara 390 mg every 8 weeks |
| NS-02 | 34 | male | SES-CD not noted; baseline scope—“The colon (entire examined portion) appeared normal. The ileocecal valve severely ulcerated and strictured unable to traverse into the terminal ileum.” | ileocecal | ileocecal | none |
| NS-03 | 21 | male | SES-CD 4, Montreal Classification A1L1p | ileum | ileum | imuran 150 mg daily |
| S-01 | 27 | female | Montreal A2 (L3 + L4) B3p (estimate using clinical summaries) | ileum | ileum | Stelara 260 mg once prior to enrollment |
| S-02 | 22 | male | SES-CD 11 | ileum | ileum | Humira 40 mg every other week; budesonide 9 mg daily |